<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867891</url>
  </required_header>
  <id_info>
    <org_study_id>SIRA</org_study_id>
    <nct_id>NCT02867891</nct_id>
  </id_info>
  <brief_title>Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial</brief_title>
  <acronym>SIRA</acronym>
  <official_title>Multicenter, Observational Trial to Determine the Response Rate of Sorafenib and Donor Lymphocyte Infusions (DLI) Versus Best Available Treatment (BAT) in FLT3-ITD-mutant AML Relapse After Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Zeiser</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial the investigators will evaluate the outcomes of 4 pre‐defined groups of
      individuals according to the therapeutic intervention. The investigators will determine the
      outcome of each group by monitoring the survival and the response rates of patients with
      FLT3-ITD AML relapse after allo-HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The preliminary data of the investigators demonstrate potent activity of Sorafenib combined
      with Donor lymphocyte infusions (DLI) in relapse of FLT3-ITD+ Acute myeloid leukemia (AML)
      after allogeneic hematopoietic cell transplantation (allo-HSCT). The investigators therefore
      launched an observational multicenter trial. The outcomes are assessed in 4 pre‐defined
      groups of individuals according to the therapeutic intervention (chemotherapy-alone-group,
      chemotherapy/DLI group, sorafenib alone group and sorafenib/DLI group). The specific
      interventions to the subjects of the study are assigned by the individual transplant center.
      The investigators will determine the outcome of each group by monitoring the survival and the
      response rates (complete remission, disease burden reduction, no response) of patients with
      FLT3-ITD AML relapse after allo-HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>10 years</time_frame>
    <description>The primary endpoint is response to treatment, defined as the number of participants that archive a complete remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of the participants</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine levels (Interleukin (IL)-15, Interferon-gamma, IL-6) of the participants.</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with acute graft-versus-host disease (GvHD).</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">396</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <description>The specific interventions to the subjects of the study are assigned by the individual transplant center</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy/DLI</arm_group_label>
    <description>The specific interventions to the subjects of the study are assigned by the individual transplant center</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib alone</arm_group_label>
    <description>The specific interventions to the subjects of the study are assigned by the individual transplant center</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib/DLI</arm_group_label>
    <description>The specific interventions to the subjects of the study are assigned by the individual transplant center</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum cytokine levels (IL-15, IFN-gamma, IL-6)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapse of FLT3-ITD AML after allogeneic hematopoietic stem cell
        transplantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology/PCR proven relapse of FLT3-ITD+ AML after allo-HSCT

          -  Age ≥18 years

          -  Treatment with either chemotherapy-alone, chemotherapy/DLI, sorafenib alone or
             sorafenib/DLI

          -  Written informed consent

          -  Ability to understand the nature of the study and the study related procedures and to
             comply with them

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Lack of informed consent

          -  Patients that cannot be classified in one of the 4 groups: chemotherapy-alone-group,
             chemotherapy/DLI group, sorafenib alone group and sorafenib/DLI group
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University of Freiburg</affiliation>
  </overall_official>
  <reference>
    <citation>Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012 Nov;26(11):2353-9. doi: 10.1038/leu.2012.105. Epub 2012 Apr 16.</citation>
    <PMID>22504140</PMID>
  </reference>
  <reference>
    <citation>De Freitas T, Marktel S, Piemontese S, Carrabba MG, Tresoldi C, Messina C, Lupo Stanghellini MT, Assanelli A, Corti C, Bernardi M, Peccatori J, Vago L, Ciceri F. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.</citation>
    <PMID>26260140</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Head of Tumor Imunnology and Immun regulation</investigator_title>
  </responsible_party>
  <keyword>FLT3-ITD</keyword>
  <keyword>AML</keyword>
  <keyword>allo-HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

